

5 May 2025

Company Announcements Office  
Australian Securities Exchange

## **Appendix 3Y Change of Director's Interest Notice**

Attached is an Appendix 3Y - Change of Director's Interest Notice in respect of changes in the relevant interests in securities held by Mr Michael Kavanagh, Chief Executive Officer & President.

On 30 April 2025, Mr Kavanagh sold a total of 100,000 Ordinary Shares. The sale of shares by Mr Kavanagh was required to fund a tax liability arising from the exercise of Nanosonics securities.

Following this change, Mr Kavanagh continues to hold 1,256,723 shares. In addition, Mr Kavanagh holds 1,569,840 Rights, which are subject to various vesting conditions.

Authorised for release by Matthew Carbines, Secretary.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Nanosonics Limited</b>
<b>ABN</b>	<b>11 095 076 896</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Michael Kavanagh
<b>Date of last notice</b>	12 March 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	a) Indirect Interest b) Indirect Interest c) Indirect Interest d) Indirect Interest e) Direct Interest f) Indirect Interest g) Indirect Interest
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	a) Performance Rights held in the Nanosonics Omnibus Equity Plan. b) Service Rights held in the Nanosonics Omnibus Equity Plan. c) Share Appreciation Rights held in the Nanosonics Omnibus Equity Plan. d) Ordinary Shares held by the trustee of the Nanosonics Employee Equity Trust. e) N/A f) Ordinary Shares held by the trustee of the Nanosonics Employee Equity Trust. g) Performance Rights held in the Nanosonics Equity Plan
<b>Date of change</b>	30 April 2025 and 1 May 2025 (Settlement Dates)

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"> <li>a) 363,925 Performance Rights held in the Nanosonics Omnibus Equity Plan</li> <li>b) 44,054 Service Rights held in the Nanosonics Omnibus Equity Plan</li> <li>c) 283,930 Share Appreciation Rights held in the Nanosonics Omnibus Equity Plan</li> <li>d) 673,360 (Indirect) Ordinary Shares</li> <li>e) 683,363 (Direct) Ordinary Shares</li> <li>f) 856,017 Performance Rights held in the Nanosonics Equity Plan</li> <li>g) 21,914 Service Rights held in the Nanosonics Equity Plan</li> </ul>
<b>Class</b>	<ul style="list-style-type: none"> <li>a) Performance Rights (Nanosonics Omnibus Equity Plan)</li> <li>b) Service Rights</li> <li>c) Share Appreciation Rights</li> <li>d) Ordinary Shares</li> <li>e) Ordinary Shares</li> <li>f) Performance Rights (Nanosonics Equity Plan)</li> <li>g) Service Rights (Nanosonics Equity Plan)</li> </ul>
<b>Number acquired</b>	Nil
<b>Number disposed</b>	100,000 Ordinary Shares (being 50,000 Ordinary Shares with a settlement date of 30 April 2025, and 50,000 Ordinary Shares with a settlement date of 1 May 2025).
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$464,978.88 (ex brokerage) in total
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>a) 363,925 Performance Rights held in the Nanosonics Omnibus Equity Plan</li> <li>b) 44,054 Service Rights held in the Nanosonics Omnibus Equity Plan</li> <li>c) 283,930 Share Appreciation Rights held in the Nanosonics Omnibus Equity Plan</li> <li>d) 0 (Indirect) Ordinary Shares</li> <li>e) 1,256,723 (Direct) Ordinary Shares</li> <li>f) 856,017 Performance Rights held in the Nanosonics Equity Plan</li> <li>g) 21,914 Service Rights held in the Nanosonics Equity Plan</li> </ul>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Sale of 100,000 Ordinary Shares held directly.  Note: In addition, 673,360 Ordinary Shares previously held indirectly in the Nanosonics Employee Equity Trust are now held directly by Mr Kavanagh.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

Director: Mr Michael Kavanagh

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

Date: 5 May 2025

---

+ See chapter 19 for defined terms.